110, Norris Canal Road, Colombo 10

Company Reg. No: PQ 165

INTERIM FINANCIAL STATEMENTS YEAR ENDED 31ST DECEMBER 2024



INTERIM FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST DECEMBER 2024

CORPORATE INFORMATION

Company : Balangoda Plantations PLC

Legal Form : Public Listed Company

Date of Incorporation : 11th June 1992

Company Registration No : P Q 165

Registered Office : 110, Norris Canal Road, Colombo 10

Board of Directors : Mr. D H S Jayawardena (Deceased on 03-02-2025)

Mr. D Hasitha S Jayawardena - Chairman / Executive Director
Mr. C R Jansz - Non Executive Director
Mr. M A N S Perera - Executive Director

Mr. K Dayaparan

- Non Executive Director

Dr. A Shakthevale

- Independent Non-Execu

Dr. A Shakthevale

- Independent Non-Executive Director (resigned w.e.f. 01-10-2024)

Mr. D S K Amarasekera

- Independent Non-Executive Director (resigned w.e.f. 01-10-2024)

- Senior Independent Director (appointed w.e.f. 01-10-2024)

Dr. R A Fernando - Independent Non-Executive Director (appointed w.e.f. 01-10-2024)

Mr. P A Jayatunga - Executive Director (appointed w.e.f. 17-02-2025)

Secretary : Mr. P A Jayatunga

833, Sirimavo Bandaranaike Mawatha

Colombo 14.

Telephone 2524734 / 2522871

Registrars : Central Depositor Systems (Pvt) Limited (CDS)

Ground Floor, M & M Centre 341/5, Kotte Road, Rajagiriya.

Auditors : Messrs. KPMG (Chartered Accountants)

32A, Sir Mohomad Macan Markar Mawatha

Colombo 03.

Bankers : Hatton National Bank PLC

Ratnapura Branch Senanayake Mawatha

Ratnapura

Parent Company : Melstacorp PLC

110, Norris Canal Road

Colombo 10.

INTERIM FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST DECEMBER 2024

STATEMENT OF FINANCIAL POSITION				
	Unaudited	Audited		
As at	31/12/2024	31/12/2023		
	Rs '000	Rs '000		
ASSETS				
Non Current Assets				
Right of Use Assets	454,638	398,966		
Immovable Leased Assets	349	366		
Property, Plant and Equipment	1,373,645	1,425,087		
Intangible Assets	992	1,256		
Investment Property	506,250	452,755		
Bearer Biological Assets	1,608,815	1,740,190		
Consumable Biological Assets	3,372,437	2,995,453		
Financial Assets Measured at FVOCI	742	409		
	7,317,868	7,014,482		
Current Assets				
Produce on Bearer Biological Assets	8,729	5,296		
Inventories	538,312	549,720		
Trade and Other Receivables	147,997	128,366		
Amounts due from Related Company	6,470	30,103		
Other Financial Assets Measured at Amortised Cost	40.055	22.965		
Cash and Cash Equivalents	40,955 742,463	23,865		
Total Assets	8,060,331	737,350 7,751,832		
EQUITY AND LIABILITIES	0,000,331	7,731,032		
Equity				
Stated Capital	2,359,091	2,359,091		
Revaluation Reserves	760,008	760,008		
Timber Reserves	3,146,297	2,769,314		
FVOCI Reserve	593	260		
Accumulated Losses	(2,516,964)	(2,750,712)		
Total Equity	3,749,025	3,137,961		
Non Current Liabilities		•		
Interest Bearing Loans and Borrowings		415,034		
Retirement Benefit Obligations	1,215,643	903,264		
Deferred Tax Liability	1,565,205	1,444,784		
Deferred Income	101,933	111,864		
Lease Liability	516,951	444,828		
•	3,399,732	3,319,774		
Current Liabilities				
Interest Bearing Loans and Borrowings	132,609	575,000		
Lease Liability	5,721	4,134		
Trade and Other Payables	466,771	361,477		
Amounts due to Related Companies	4,321	949		
Bank Overdraft	302,152	352,537		
75 (17 1 19)	911,574	1,294,097		
Total Liabilities	4,311,306	4,613,871		
Total Equity and Liabilities	8,060,331	7,751,832		
Net Assets per Share It is contified that these interim financial statements have been preparational statements.	79.31	66.38		

It is certified that these interim financial statements have been prepared in compliance with the requirements of the Companies Act No. 7 of 2007.

- Signed -D S Heenatigalage

General Manager - Finance

The board of directors are responsible for the preparation and presentation of these Financial Statements. Approved & signed for and on behalf of the board of directors of Balangoda Plantations PLC by;

- Signed -- Signed -C R Jansz M A N S Perera Director Director Colombo, 25th February 2025

INTERIM FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST DECEMBER 2024

STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME 03 Months 03 Months Unaudited Audited Year ended ended ended Variance Year ended Variance 31/12/2024 31/12/2023 31/12/2024 31/12/2023 Rs. '000 % Rs. '000 Rs. '000 Rs. '000 % Revenue 1,175,524 835,510 41 4,873,820 4,129,862 18 Cost of sales (1,145,221)(807,663)(42)(4,028,248)(3,752,619)(7) 9 Gross profit 30,303 27,847 845,572 377,243 124 Other income 92,767 39,415 135 183,793 157,077 17 Gain on changes in fair value of biological assets 184,443 47,012 292 380,417 401,038 (5) (91) Administrative expenses (79,135)(41,423)(191,007)(157,828)(21)_(15,959) Other expenses (75,637)(471)(100,000)(99,638)(0)Profit from operating activities 65 152,741 72,380 111 1,118,775 677,892 Finance income 572 378 51 1,945 5,194 (63)(28,539)50 (158,044)(328, 234)52 Finance costs (57,281)Net Finance costs (27,967)51 (156,099)(323,040)52 (56,903)**Profit before taxation** 171 124,774 15,477 706 962,676 354,852 Income tax expense (73,989)(189,878)(285,782)(100)Profit for the period 50,785 15,477 228 772,798 69,070 1,019 Other comprehensive income / (Expenses) Items that will not be Reclassified to Profit or Loss Gain on Revaluation - Assets transferred from PPE to Investment Property 26,170 Actuarial Gain/(Loss) on Retirement Benefit Obligations (231,524)77,513 (231,524)35,884 Deferred Tax Charge on Revaluation Surplus (7,851)Deferred Tax on Actuarial Gain on Retirement Benefit Obligations 69,457 (10,765)69,457 Net change in the fair value of financial assets measured at FVOCI 249 (24)333 217 77,489 (161,734)Total other comprehensive income/(Expense) (161,818)43,655 Total comprehensive income (111,033)92,966 611,064 112,725 1.07 0.33 Basic earnings per Share 16.35 1.46

Figures in brackets indicate deductions. The above figures are not audited

INTERIM FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST DECEMBER 2024

STATEMENT OF CHANGES IN EQUITY **FVOCI** Accumulated Total Stated Revaluation Timber Pending Capital Reserves Reserves Reserves Allotment Loss Equity Rs. '000 Rs.'000 Rs. '000 Rs. '000 Rs. '000 Rs. '000 Rs. '000 Balance as at 1st January 2023 350,000 741,689 43 2,169,642 3,280,333 2,363,625 (2,344,666)Profit for the year 69,070 69,070 Other comprehensive Income, net of tax 18,319 217 25,118 43,654 Transferred to timber Reserve 405,689 (405,689)Transferred to right Issue Issue of Shares 2,009,091 (2,009,091)Refund of unaccepted shares applications (160,551)(160,551)Dividend Paid (94,545)(94,545)Balance as at 31st December 2023 2,359,091 760,008 2,769,314 260 (2,750,712)3,137,961 Balance as at 1st January 2024 2,359,091 760,008 2,769,314 260 (2,750,712)3,137,961 Profit for the year 772,798 772,798 Transferred to timber Reserve 376,983 (376,983)Other comprehensive Income / (Expenses), net of tax 333 (162,067)(161,734)

3,146,297

Figures in brackets indicate deductions. The above figures are not audited

Balance as at 31st December 2024

2,359,091

760,008

593

(2,516,964)

3,749,025

INTERIM FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST DECEMBER 2024

For the year ended Unaudited 31/12/2024 31/12/2023 Rx. 900 Audited 13/12/2024 Rx. 900 Cash Flows From Operating Activities Profit Before Taxation 962,676 354,851 Adjustments for Depreciation and Amortization 214,729 226,088 Despreciation and Amortization Flubber 100,000 85,791 Write off Bearer Biological Assets - 9,336 Provision for Write off of ther Receivables - 984 Provision for Property, Plant and Equipment Interest Income (1,945) (5,194) Gain on Disposal of Property, Plant and Equipment Interest Income (1,945) (5,194) Provision for Retirement Benefit Obligations 267,562 213,337 Amortization of Government Grants (9,932) (2,244) Interest Expenses 158,044 328,235 Change in Fair Value Gain on Investment properties (35,698) (401,038) Operating Profit before Working Capital Changes 1,257,355 762,141 Working Capital Changes 7,976 124,917 Operacy Chercase in Trade and Other Receivables (1,963) (13,767) Decreases (Increase) in in mounts Due 1 From Related Compan	STATEMENT OF CASH FLOWS					
Profit beyear ended Na. 1902		Unaudited	Audited			
Rs. 000	For the year ended					
Profit Before Taxation						
Adjustments for Depreciation and Amortization Depreciation and Amortization Depreciation and Amortization Depreciation and Amortization 100,000 85,791 Write off Bearer Biological Assets - 9,336 Provision for Nirtie off of other Receivables - 984 Provision for Nosbelet Inventory - 963 Gain on Disposal of Property, Plant and Equipment (3,300) (5,350) Interest Income (1,945) (5,194) Provision for Retirement Benefit Obligations 267,562 213,337 Amortization of Government Grants (9,932) (9,214) (1,945)						
Depreciation and Amortization 19,4729 226,088 100,000 85,791 Write off Bearer Biological Assets - 9,336 Provision for Write off of ther Receivables - 984 Provision for Owntentory 963 63,500 63,	Profit Before Taxation	962,676	354,851			
Depreciation and Amortization 19,4729 226,088 100,000 85,791 Write off Bearer Biological Assets - 9,336 Provision for Immature Plantation-Rubber - 9,336 Provision for Obsolete Inventory - 963 63,000 (6,350) (Adjustments for					
Write off Bearer Biological Assets - 9,336 Provision for /Write off of the Receivables - 984 Provision for obsolete Inventory - 963 Gain on Disposal of Property, Plant and Equipment (3,300) (6,350) Interest Income (1,945) (5,194) Provision for Retirement Benefit Obligations 267,562 213,337 Amortization of Government Grants (9,932) (9,214) Interest Expenses 158,044 328,235 Change in Fair Value Gain on Investment properties (53,495) (35,6984) Gain on Changes in Fair Value of Biological Assets (376,984) (401,038) Operating Profit before Working Capital Changes 7,976 124,917 Working Capital Changes 7,976 124,917 Morease (Increase) in inventories (19,630) (13,767) Increase (Increase) in Amounts Due From Related Companies 23,633 (3,404) Increase / (Decrease) in Trade and Other Payables 105,294 (52,107) Increase / (Decrease) in Trade and Other Payables 105,294 (52,107) Increase / (Decrease) in Tad		214,729	226,088			
Provision for /Write off of other Receivables - 984 Provision for obsolete Inventory - 963 Gain on Disposal of Property, Plant and Equipment (1,945) (5,194) Provision for Retirement Benefit Obligations 267,562 213,337 Amortization of Government Grants (9,932) (9,214) Interest Expenses 158,044 328,223 Change in Fair Value Gain on Investment properties (53,495) (35,648) Gain on Changes in Fair Value of Biological Assets (376,984) (401,038) Operating Profit before Working Capital Changes 1,257,355 762,141 Working Capital Changes 7,976 124,917 Operates (Increase) in Inventories 7,976 124,917 (Increase) / Decrease in Trade and Other Receivables (19,630) (13,747) Decrease (Increase) in Jace and Other Payables 105,294 (52,107) Increase / (Decrease) in Trade and Other Payables 105,294 (52,107) Increase / (Decrease) in Amounts Due to Related Companies 3,373 23 Cash Generated from Operations 1,378,001 817,803		100,000				
Provision for obsolete Inventory		-				
Gain on Disposal of Property, Plant and Equipment (3,300) (6,350) Interest Income (1,945) (5,194) Provision for Retirement Benefit Obligations 267,562 (213,337) Amortization of Government Grants (9,932) (9,214) Interest Expenses 158,044 328,235 Change in Fair Value Gain on Investment properties (33,495) (35,648) Gain on Changes in Fair Value of Biological Assets (376,984) (401,038) Operating Profit before Working Capital Changes 1,257,355 762,141		_				
Interest Income		(3,300)				
Amortization of Government Grants (9,932) (9,214) Interest Expenses (158,044) 328,235 (158,048) (35,648) (361,049) (35,648) (361,049) (35,648) (361,049) (35,648) (361,049) (361						
Interest Expenses		267,562	213,337			
Change in Fair Value Gain on Investment properties G35,495 G35,648 Gain on Changes in Fair Value of Biological Assets G376,984 (401,038) (401,038)		N 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1				
Gain on Changes in Fair Value of Biological Assets 376,984 (401,038)	1					
Note Cash						
Working Capital Changes 7,976 124,917 Decrease/ (Increase) in inventories 1,9630 (13,767) Decrease/ (Increase) in Trade and Other Receivables 23,633 (3,404) Increase/ (Decrease) in Trade and Other Payables 105,294 (52,107) Increase / (Decrease) in Amounts Due to Related Companies 3,373 23 Cash Generated from Operations 1,378,001 817,803 Retirement Benefit Obligations Paid (186,706) (177,205) Interest Paid (23,543) (59,136) Net Cash Generated from / (Used in) Operating Activities 1,167,752 581,462 Cash Flows From Investing Activities 1,945 5,194 Interest Received 1,945 5,194 Purchase of Property, Plant and Equipment (52,790) (56,784) Acquisition of Intangible Assets (166) - Acquisition of Investment Property - (2,415) Investment in Immature Bearer Biological Assets (55,965) (97,361) Proceeds from Disposal of Property, Plant And Equipment 3,300 6,350 Net Cash Generated from/ (Used In) Investi						
Decrease (Increase) in inventories (Increase) / Decrease in Trade and Other Receivables (19,630) (13,767) Decrease / (Increase) in Amounts Due From Related Companies (23,633) (3,404) Increase / (Decrease) in Trade and Other Payables (105,294) (52,107) Increase / (Decrease) in Amounts Due to Related Companies (3,373) 23 Cash Generated from Operations (18,78,001) 817,803 Retirement Benefit Obligations Paid (186,706) (177,205) Interest Paid (23,543) (59,136) Net Cash Generated from / (Used in) Operating Activities (1,167,752) 581,462 Cash Flows From Investing Activities Interest Received (1,945) 5,194 Purchase of Property, Plant and Equipment (52,790) (56,784) Acquisition of Intangible Assets (166) - (2,415) Investment in Immature Bearer Biological Assets (55,965) (97,361) Investment in Consumable Bialogical Assets (55,965) (97,361) Investment in Consumable Bialogical Assets (5,965) (97,361) Net Cash Generated from / (Used In) Investing Activities (103,676) (147,900) Cash Flows from Financing Activities (103,676) (147,900) Cash Flows from Financing Activities (996,601) (2,864,25) Repayment of Long Term Borrowings (927,368) (2,555,143) Repayment of Long Term Borrowings (927,368) (2,555,143) Repayment of Long Term Borrowings (927,368) (2,555,143) Repayment of Lease Liabilities (996,601) (2,866,420) Net Cash Generated from/(Used In) Financing Activities (996,601) (2,866,420) Net Cash Generated from/(Used In) Financing Activities (996,601) (2,866,420) Cash and Cash Equivalents at Enginning of the Period (Note A) (261,197) (328,672) Cash and Cash Equivalents at Enginning of the Period (Note A) (261,197) (328,672) Cash and Cash Equivalents at End of the Period (Note A) (261,197) (328,672) Cash and Cash Equivalents at End of the Period (Note A) (261,197) (328,672) Cash and Cash Equivalents at End of the Period (Note A) (261,197) (328,672) Cash and Cash Equivalents (23,28,672) (328,672) (328,672) Cash		1,207,000	, , , , , , , ,			
(Increase) / Decrease in Trade and Other Receivables (19,630) (13,767) Decrease / ((Increase) in Amounts Due From Related Companies (15,293) (3,404) Increase / (Decrease) in Trade and Other Payables (15,2107) Increase / (Decrease) in Amounts Due to Related Companies (15,2107) Increase / (Decrease) in Amounts Due to Related Companies (186,706) (177,203) Retirement Benefit Obligations Paid (186,706) (177,205) Interest Paid (23,543) (59,136) Net Cash Generated from / (Used in) Operating Activities (1,67,752 581,462) Cash Flows From Investing Activities (1,945 5,194 Purchase of Property, Plant and Equipment (52,790) (56,784) Acquisition of Intangible Assets (166) - (2,415) Investment in Immature Bearer Biological Assets (55,965) (97,361) Investment in Immature Bearer Biological Assets (55,965) (79,361) Investment in Consumable Bialogical Assets (2,884) Proceeds from Disposal of Property, Plant And Equipment (3,300) (6,350) Net Cash Generated from / (Used In) Investing Activities (103,676) (147,900) Cash Flows from Financing Activities (997,368) (2,555,143) Repayment of Long Term Borrowings (927,368) (2,555,143) Repayment of Lease Liabilities (69,233) (56,187) Refund of Unaccepted Shares Applications (160,551) Dividend Paid (1,50) (1,50) (1,50) Net Cash Generated from / (Used In) Financing Activities (996,601) (2,866,426) Net Increase / (Decrease) in Cash and Cash Equivalents (32,8672) (2,432,864) Cash and Cash Equivalents at End of the Period (Note A) (261,197) (328,672) Read (302,152) (352,537)		7.076	124.017			
Decrease (Increase) in Amounts Due From Related Companies 105,294 (52,107) (52,1			,			
Increase / (Decrease) in Trade and Other Payables 105,294 (52,107) Increase / (Decrease) in Amounts Due to Related Companies 3,373 23 Cash Generated from Operations 1,378,001 817,803 Retirement Benefit Obligations Paid (186,706) (177,205) Interest Paid (23,543) (59,136) Net Cash Generated from / (Used in) Operating Activities 1,167,752 581,462 Cash Flows From Investing Activities 1,945 5,194 Purchase of Property, Plant and Equipment (52,790) (56,784) Acquisition of Intangible Assets (166) - (2,415) Investment in Immature Bearer Biological Assets (55,965) (97,361) Investment in Consumable Bialogical Assets - (2,884) Proceeds from Disposal of Property, Plant And Equipment 3,300 6,350 Net Cash Generated from / (Used In) Investing Activities (103,676) (147,900) Cash Flows from Financing Activities (927,368) (2,555,143) Repayment of Long Term Borrowings (927,368) (2,555,143) Refund of Unaccepted Shares Applications (160,551) Dividend Paid - (94,545) Net Cash Generated from/(Used In) Financing Activities (996,601) (2,866,420) Net Increase / (Decrease) in Cash and Cash Equivalents (7,475) (2,432,864) Cash and Cash Equivalents at End of the Period (Note A) (261,197) (328,672) Cash and Cash Equivalents at End of the Period (Note A) (261,197) (328,672) Cash and Cash Equivalents (302,152) (352,537)						
Cash Generated from Operations 1,378,001 817,803 Retirement Benefit Obligations Paid (186,706) (177,205) Interest Paid (23,543) (59,136) Net Cash Generated from / (Used in) Operating Activities 1,167,752 581,462 Cash Flows From Investing Activities 1,945 5,194 Interest Received 1,945 5,194 Purchase of Property, Plant and Equipment (52,790) (56,784) Acquisition of Investment Property - (2,415) Investment in Immature Bearer Biological Assets (55,965) (97,361) Investment in Consumable Bialogical Assets - (2,884) Proceeds from Disposal of Property, Plant And Equipment 3,300 6,330 Net Cash Generated from / (Used In) Investing Activities (103,676) (147,900) Cash Flows from Financing Activities (927,368) (2,555,143) Repayment of Long Term Borrowings (927,368) (2,555,143) Repayment of Lease Liabilities (6,923) (56,187) Refund of Unaccepted Shares Applications - (160,551) Dividend Paid						
Retirement Benefit Obligations Paid (186,706) (177,205) Interest Paid (23,543) (59,136) Net Cash Generated from / (Used in) Operating Activities 1,167,752 581,462 Cash Flows From Investing Activities 1,945 5,194 Interest Received 1,945 5,194 Purchase of Property, Plant and Equipment (52,790) (56,784) Acquisition of Intengible Assets (166) - Acquisition of Investment Property - (2,415) Investment in Immature Bearer Biological Assets (55,965) (97,361) Investment in Consumable Bialogical Assets - (2,884) Proceeds from Disposal of Property, Plant And Equipment 3,300 6,350 Net Cash Generated from / (Used In) Investing Activities (103,676) (147,900) Cash Flows from Financing Activities (927,368) (2,555,143) Repayment of Long Term Borrowings (927,368) (2,555,143) Repayment of Lease Liabilities (69,233) (56,187) Refund of Unaccepted Shares Applications - (160,551) Dividend Paid - </td <td>Increase / (Decrease) in Amounts Due to Related Companies</td> <td></td> <td></td>	Increase / (Decrease) in Amounts Due to Related Companies					
Interest Paid	Cash Generated from Operations	1,378,001	817,803			
Interest Paid	Retirement Benefit Obligations Paid	(186,706)	(177,205)			
Cash Flows From Investing Activities 1,945 5,194 Interest Received 1,945 5,194 Purchase of Property, Plant and Equipment (52,790) (56,784) Acquisition of Intangible Assets (166) - Acquisition of Investment Property - (2,415) Investment in Immature Bearer Biological Assets (55,965) (97,361) Investment in Consumable Bialogical Assets - (2,884) Proceeds from Disposal of Property, Plant And Equipment 3,300 6,350 Net Cash Generated from / (Used In) Investing Activities (103,676) (147,900) Cash Flows from Financing Activities 8 (2,555,143) Repayment of Long Term Borrowings (927,368) (2,555,143) Repayment of Lease Liabilities (69,233) (56,187) Refund of Unaccepted Shares Applications - (160,551) Dividend Paid - (94,545) Net Cash Generated from/(Used In) Financing Activities (996,601) (2,866,426) Net Increase / (Decrease) in Cash and Cash Equivalents 67,475 (2,432,864) Cash and Cash Equivalents at	<u> </u>					
Interest Received 1,945 5,194 Purchase of Property, Plant and Equipment (52,790) (56,784) Acquisition of Intangible Assets (166) - (2,415) Acquisition of Investment Property - (2,415) Investment in Immature Bearer Biological Assets (55,965) (97,361) Investment in Consumable Bialogical Assets - (2,884) Proceeds from Disposal of Property, Plant And Equipment 3,300 6,350 Net Cash Generated from / (Used In) Investing Activities (103,676) (147,900) Cash Flows from Financing Activities (927,368) (2,555,143) Repayment of Long Term Borrowings (927,368) (2,555,143) Repayment of Lease Liabilities (69,233) (56,187) Refund of Unaccepted Shares Applications - (160,551) Dividend Paid - (94,545) Net Cash Generated from/(Used In) Financing Activities (996,601) (2,866,426) Net Increase / (Decrease) in Cash and Cash Equivalents (67,475) (2,432,864) Cash and Cash Equivalents at Beginning of the Period (328,672) 2,104,192 Cash and Cash Equivalents at End of the Period (Note A) (261,197) (328,672) Note A Cash and Cash Equivalents 40,955 23,865 Bank Overdraft (302,152) (352,537)	Net Cash Generated from / (Used in) Operating Activities	1,167,752	581,462			
Interest Received 1,945 5,194 Purchase of Property, Plant and Equipment (52,790) (56,784) Acquisition of Intangible Assets (166) - (2,415) Acquisition of Investment Property - (2,415) Investment in Immature Bearer Biological Assets (55,965) (97,361) Investment in Consumable Bialogical Assets - (2,884) Proceeds from Disposal of Property, Plant And Equipment 3,300 6,350 Net Cash Generated from / (Used In) Investing Activities (103,676) (147,900) Cash Flows from Financing Activities (927,368) (2,555,143) Repayment of Long Term Borrowings (927,368) (2,555,143) Repayment of Lease Liabilities (69,233) (56,187) Refund of Unaccepted Shares Applications - (160,551) Dividend Paid - (94,545) Net Cash Generated from/(Used In) Financing Activities (996,601) (2,866,426) Net Increase / (Decrease) in Cash and Cash Equivalents (67,475) (2,432,864) Cash and Cash Equivalents at Beginning of the Period (328,672) 2,104,192 Cash and Cash Equivalents at End of the Period (Note A) (261,197) (328,672) Note A Cash and Cash Equivalents 40,955 23,865 Bank Overdraft (302,152) (352,537)	Cash Flows From Investing Activities					
Acquisition of Intangible Assets (166) - Acquisition of Investment Property - (2,415) Investment in Immature Bearer Biological Assets (55,965) (97,361) Investment in Consumable Bialogical Assets - (2,884) Proceeds from Disposal of Property, Plant And Equipment 3,300 6,350 Net Cash Generated from / (Used In) Investing Activities (103,676) (147,900) Cash Flows from Financing Activities (927,368) (2,555,143) Repayment of Long Term Borrowings (927,368) (2,555,143) Repayment of Lease Liabilities (69,233) (56,187) Refund of Unaccepted Shares Applications - (160,551) Dividend Paid - (94,545) Net Cash Generated from/(Used In) Financing Activities (996,601) (2,866,426) Net Increase / (Decrease) in Cash and Cash Equivalents 67,475 (2,432,864) Cash and Cash Equivalents at End of the Period (328,672) 2,104,192 Cash and Cash Equivalents at End of the Period (Note A) (261,197) (328,672) Note A Cash and Cash Equivalents 40,955 23,865 Bank Overdraft (302,152) <td></td> <td>1,945</td> <td>5,194</td>		1,945	5,194			
Acquisition of Investment Property - (2,415)			(56,784)			
Investment in Immature Bearer Biological Assets (55,965) (97,361) Investment in Consumable Bialogical Assets - (2,884) Proceeds from Disposal of Property, Plant And Equipment 3,300 6,350 Net Cash Generated from / (Used In) Investing Activities (103,676) (147,900) Cash Flows from Financing Activities Repayment of Long Term Borrowings (927,368) (2,555,143) Repayment of Lease Liabilities (69,233) (56,187) Refund of Unaccepted Shares Applications - (160,551) Dividend Paid - (94,545) Net Cash Generated from/(Used In) Financing Activities (996,601) (2,866,426) Net Increase / (Decrease) in Cash and Cash Equivalents (328,672) 2,104,192 Cash and Cash Equivalents at End of the Period (Note A) (261,197) (328,672) Note A Cash and Cash Equivalents 40,955 23,865 Bank Overdraft (302,152) (352,537)		(166)	(2.415)			
Investment in Consumable Bialogical Assets - (2,884)		- (55.965)				
Proceeds from Disposal of Property, Plant And Equipment 3,300 6,350 Net Cash Generated from / (Used In) Investing Activities (103,676) (147,900) Cash Flows from Financing Activities Repayment of Long Term Borrowings (927,368) (2,555,143) Repayment of Lease Liabilities (69,233) (56,187) Refund of Unaccepted Shares Applications - (160,551) Dividend Paid - (94,545) Net Cash Generated from/(Used In) Financing Activities (996,601) (2,866,426) Net Increase / (Decrease) in Cash and Cash Equivalents 67,475 (2,432,864) Cash and Cash Equivalents at Beginning of the Period (328,672) 2,104,192 Cash and Cash Equivalents at End of the Period (Note A) (261,197) (328,672) Note A Cash and Cash Equivalents 40,955 23,865 Bank Overdraft (302,152) (352,537)	· · · · · · · · · · · · · · · · · · ·	(33,903)				
Net Cash Generated from / (Used In) Investing Activities (103,676) (147,900) Cash Flows from Financing Activities 8 (927,368) (2,555,143) Repayment of Long Term Borrowings (69,233) (56,187) Refund of Unaccepted Shares Applications - (160,551) Dividend Paid - (94,545) Net Cash Generated from/(Used In) Financing Activities (996,601) (2,866,426) Net Increase / (Decrease) in Cash and Cash Equivalents 67,475 (2,432,864) Cash and Cash Equivalents at Beginning of the Period (328,672) 2,104,192 Cash and Cash Equivalents at End of the Period (Note A) (261,197) (328,672) Note A (28) (302,152) (352,537)		3,300				
Repayment of Long Term Borrowings (927,368) (2,555,143) Repayment of Lease Liabilities (69,233) (56,187) Refund of Unaccepted Shares Applications - (160,551) Dividend Paid - (94,545) Net Cash Generated from/(Used In) Financing Activities (996,601) (2,866,426) Net Increase / (Decrease) in Cash and Cash Equivalents 67,475 (2,432,864) Cash and Cash Equivalents at Beginning of the Period (328,672) 2,104,192 Cash and Cash Equivalents at End of the Period (Note A) (261,197) (328,672) Note A (284) (284) (284) Cash and Cash Equivalents 40,955 23,865 Bank Overdraft (302,152) (352,537)		(103,676)				
Repayment of Long Term Borrowings (927,368) (2,555,143) Repayment of Lease Liabilities (69,233) (56,187) Refund of Unaccepted Shares Applications - (160,551) Dividend Paid - (94,545) Net Cash Generated from/(Used In) Financing Activities (996,601) (2,866,426) Net Increase / (Decrease) in Cash and Cash Equivalents 67,475 (2,432,864) Cash and Cash Equivalents at Beginning of the Period (328,672) 2,104,192 Cash and Cash Equivalents at End of the Period (Note A) (261,197) (328,672) Note A (284) (284) (284) Cash and Cash Equivalents 40,955 23,865 Bank Overdraft (302,152) (352,537)	Cash Flows from Financing Activities					
Repayment of Lease Liabilities (69,233) (56,187) Refund of Unaccepted Shares Applications - (160,551) Dividend Paid - (94,545) Net Cash Generated from/(Used In) Financing Activities (996,601) (2,866,426) Net Increase / (Decrease) in Cash and Cash Equivalents 67,475 (2,432,864) Cash and Cash Equivalents at Beginning of the Period (328,672) 2,104,192 Cash and Cash Equivalents at End of the Period (Note A) (261,197) (328,672) Note A - 40,955 23,865 Bank Overdraft (302,152) (352,537)		(927.368)	(2.555.143)			
Refund of Unaccepted Shares Applications - (160,551) Dividend Paid - (94,545) Net Cash Generated from/(Used In) Financing Activities (996,601) (2,866,426) Net Increase / (Decrease) in Cash and Cash Equivalents 67,475 (2,432,864) Cash and Cash Equivalents at Beginning of the Period (328,672) 2,104,192 Cash and Cash Equivalents at End of the Period (Note A) (261,197) (328,672) Note A Cash and Cash Equivalents 40,955 23,865 Bank Overdraft (302,152) (352,537)						
Net Cash Generated from/(Used In) Financing Activities (996,601) (2,866,426) Net Increase / (Decrease) in Cash and Cash Equivalents 67,475 (2,432,864) Cash and Cash Equivalents at Beginning of the Period (328,672) 2,104,192 Cash and Cash Equivalents at End of the Period (Note A) (261,197) (328,672) Note A Cash and Cash Equivalents 40,955 23,865 Bank Overdraft (302,152) (352,537)		· - 1	(160,551)			
Net Increase / (Decrease) in Cash and Cash Equivalents 67,475 (2,432,864) Cash and Cash Equivalents at Beginning of the Period (328,672) 2,104,192 Cash and Cash Equivalents at End of the Period (Note A) (261,197) (328,672) Note A 23,865 Cash and Cash Equivalents 40,955 23,865 Bank Overdraft (302,152) (352,537)		-				
Cash and Cash Equivalents at Beginning of the Period (328,672) 2,104,192 Cash and Cash Equivalents at End of the Period (Note A) (261,197) (328,672) Note A 40,955 23,865 Bank Overdraft (302,152) (352,537)	Net Cash Generated from/(Used In) Financing Activities	(996,601)	(2,866,426)			
Cash and Cash Equivalents at Beginning of the Period (328,672) 2,104,192 Cash and Cash Equivalents at End of the Period (Note A) (261,197) (328,672) Note A 40,955 23,865 Bank Overdraft (302,152) (352,537)	Net Increase / (Decrease) in Cash and Cash Equivalents	67,475	(2,432,864)			
Note A Cash and Cash Equivalents 40,955 23,865 Bank Overdraft (302,152) (352,537)		(328,672)	2,104,192			
Cash and Cash Equivalents 40,955 23,865 Bank Overdraft (302,152) (352,537)	Cash and Cash Equivalents at End of the Period (Note A)	(261,197)	(328,672)			
Cash and Cash Equivalents 40,955 23,865 Bank Overdraft (302,152) (352,537)	Note A					
Bank Overdraft (302,152) (352,537)		40.955	23 865			
	•					

Figures in brackets indicate deductions.

The above figures are not audited

INTERIM FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST DECEMBER 2024

NOTES TO THE FINANCIAL STATEMENTS						
01. Segmental Information						
For the year ended	31/12/2024 Rs. '000 Tea	31/12/2023 Rs. '000 Tea	31/12/2024 Rs. '000 Rubber	31/12/2023 Rs. '000 Rubber	31/12/2024 Rs. '000 Total	31/12/2023 Rs. '000 Total
(a) Segment Results						
Revenue	4,422,176	3,783,093	451,644	346,769	4,873,820	4,129,862
Cost of Sales	(3,551,573)		(476,675)	(541,490)	(4,028,248)	(3,752,619)
Segment Results	870,603	571,964	(25,031)	(194,721)	845,572	377,243
Unallocated Other Operating Income Gain on Change in Fair Value of Biological Asse	et				183,793 380,417	157,077 401,038
Administrative Expenses					(191,007)	(157,828)
Other Expenses					(100,000)	(99,638)
Net Finance Cost					(156,099)	(323,040)
Profit Before Taxation					962,676	354,852
Income tax charge					(189,878)	(285,782)
Profit for the Year					772,798	69,070
(b) Segment Assets						
As at	31/12/2024	31/12/2023	31/12/2024	31/12/2023	31/12/2024	31/12/2023
	Rs. '000	Rs. '000	Rs. '000	Rs. '000	Rs. '000	Rs. '000
Non Current Assets	2,218,373	2,177,376	1,643,314	1,761,280	3,861,687	3,938,656
Current Assets	593,086	628,097	86,784	63,797	679,870	691,894
Unallocated	2,811,459	2,805,473	1,730,098	1,825,077	4,541,557	4,630,550
Non Current Assets					3,456,181	3,075,827
Current Assets					62,593	45,457
Total Assets					8,060,331	7,751,834
Segment Liabilities						
Non Current Liabilities	1,055,363	1,230,547	160,281	227,024	1,215,644	1,457,571
Current Liabilities	282,497	405,666	46,538	74,124	329,035	479,790
Total Liabilities	1,337,860	1,636,213	206,819	301,148	1,544,679	1,937,361
Unallocated Non Current Liabilities Current Liabilities Total Liabilities					2,184,088 582,539 4,311,306	1,862,203 814,307 4,613,871
1 Stat Diagnities					1,011,000	1,013,071

Equity

3,749,025

3,137,963

INTERIM FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST DECEMBER 2024

NOTES TO THE FINANCIAL STATEMENTS

- **02** These interim financial statements of the company for the year ended 31st December 2024 were approved by the board of directors on 25th February 2025.
- **03** The interim Financial Statements have been prepared in accordance with the Accounting Policies set out in the most recent Annual Report and are in compliance with Sri Lanka Accounting Standard LKAS 34 Interim Financial Reporting.
- 04 No circumstances have arisen since the Financial Position date, which would require adjustments to or disclosure in the financial statements.
- **05** Stated Capital of Balangoda Plantations PLC amount to Rs. 2,368,363,573 represented by 47,272,726 ordinary shares and a Golden share which has special rights held by the Secretary to the Treasury.
- **06** There has not been a significant change in the nature of the contingent liabilities which were disclosed in the Annual Report for the year ended 31 December 2023.

INVESTOR INFORMATION

Year ended 31/12/2024 Year ended 31/12/2023

 Highest Price Rs.
 76.00
 88.00

 Lowest Price Rs.
 43.00
 48.00

 Last Traded Price Rs.
 72.00
 50.80

02 Directors' shareholding

01 Market Price Per Share

A statement of each Director's holding and Chief Executive Officer's holding in shares of the entity at the end of the financial period 31st December 2024

Name	As at	As at	
Mr. D H S Jayawardena (Deceased on 03-02-2025)	31/12/2024	31/12/2023	
Mr. D Hasitha S Jayawardena - Chairman / Executive Director	-	-	
Mr. C R Jansz - Non Executive Director	-	-	
Mr. K Dayaparan - Non Executive Director	-	-	
Mr. M A N S Perera - Executive Director	-	-	
Dr. A Shakthevale - Independent Non-Executive Director (resigned w.e.f. 01-10-2024)	-	-	
Mr. D S K Amarasekera - Independent Non-Executive Director (resigned w.e.f. 01-10-2024)	-	-	
Mr. M R Mihular - Senior Independent Non-Executive Director (appointed w.e.f. 01-10-2024)	-	-	
Dr. R A Fernando - Independent Non-Executive Director (appointed w.e.f. 01-10-2024)	-	-	
Mr. P A Jayatunga - Executive Director (appointed w.e.f. 17-02-2025)	-	-	
CEO'S Shareholding as at 31st December 2024			
Mr. D D Wekunagoda	-	-	

INTERIM FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST DECEMBER 2024

INVESTOR INFORMATION

03 Twenty (20) largest shareholders as at 31st December 2024

	NAME	No. of shares	% of issued capital
01	MELSTACORP PLC	35,268,300	74.61%
02	SEYLAN BANK PLC/R.A.RISHARD	420,000	0.89%
03	HATTON NATIONAL BANK PLC - CAPITAL ALLIANCE QUANTITATIVE EQ	335,981	0.71%
04	DR. M.A.A. MOHAMED AKRAM	294,655	0.62%
05	SEYLAN BANK PLC/MOHAMED MUSHTAQ FUAD	256,938	0.54%
06	ACCESS ENGINEERING PLC	251,219	0.53%
07	SEYLAN BANK PLC/MOHAMED SUBAIR FOUZAL HAQQUE	250,000	0.53%
08	MR. M.H.M. FAWSAN	200,000	0.42%
09	HATTON NATIONAL BANK PLC/MUSHTAQ MOHAMED FUAD	184,000	0.39%
10	POLGAHAWELA SANASA SOCIETIES UNION LTD	172,524	0.36%
11	SEYLAN BANK PLC/ HILINE TOWERS (PVT) LTD.	144,361	0.31%
12	AMANA BANK PLC/HI-LINE TOWERS PVT LIMITED	135,536	0.29%
13	MACKSONS HOLDINGS (PVT) LTD	130,369	0.28%
14	COCOSHELL ACTIVATED CARBON COMPANY (PRIVATE) LIMITED	120,400	0.25%
15	MRS. F.F. HANIFFA	120,000	0.25%
16	MR. G. ANURAGAVAN	112,819	0.24%
17	MR. A.K. PALLIYA GURUGE DON (DECEASED)	108,000	0.23%
18	MR. R.S. NANAYAKKARA	100,000	0.21%
19	MR. L.D.S. CHANDRASIRI	100,000	0.21%
20	SENKADAGALA FINANCE PLC/M.S.F.HAQQUE	95,000	0.20%
		38,800,102	82.08%
	Other Shareholders	8,472,624	17.92%
	TOTAL	47,272,726	100.00%

	31/12/2024	31/12/2023
Public holding % of the stated capital	25.39	25.39
Number of Shareholders representing public shareholdings	18,529	18,653
Float adjusted market capitalization (Rs. '000)	864,319	609,825

Minimum public holding

The Float adjusted market capitalization of the company falls under option 5 of Rule 7.13.1(a) of the Listing Rules of the Colombo Stock Exchange and the Company has complied with the minimum public holding requirement applicable under the said option.